Walgreens is ramping up its clinical trial offerings with Big Pharma players.
Walgreens Boots Alliance Inc. (NASDAQ:WBA) is facing tumultuous times as it grapples with a challenging turnaround, leading to a drastic decline in its stock value, marking its worst performance in over five years. The company’s shares plummeted by 18% in April, nearing a 26-year low, following a downward revision of its outlook. This revision was accompanied by concerns over decreased consumer spending and the revelation of a substantial unpaid tax liability amounting to $2.7 billion, adding to
Walmart announced it is closing down its healthcare business Tuesday. The move will impact 51 locations in five states, as well as relationships with health systems, like the one penned with Florida's Orlando Health in November.